Literature DB >> 32460681

Increases in Providers With Buprenorphine Waivers in the United States From 2016 to 2019.

Robin Ghertner1, Mir M Ali1.   

Abstract

Entities:  

Keywords:  Buprenorphine; DATA-Waiver; Drug abuse; Drug treatment; Opioid; psychopharmacology

Mesh：

Substances：

Year:  2020        PMID： 32460681     DOI： 10.1176/appi.ps.201900635

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN： 1075-2730            Impact factor:   3.084


× No keyword cloud information.
  4 in total

1.  Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.

Authors:  David Dadiomov; Maria Bolshakova; Melania Mikhaeilyan; Rebecca Trotzky-Sirr
Journal:  Harm Reduct J       Date:  2022-06-29

2.  Buprenorphine prescriber monthly patient caseloads: An examination of 6-year trajectories.

Authors:  Irineo Cabreros; Beth Ann Griffin; Brendan Saloner; Adam J Gordon; Rose Kerber; Bradley D Stein
Journal:  Drug Alcohol Depend       Date:  2021-09-22       Impact factor: 4.492

3.  Where Opioid Overdose Patients Live Far From Treatment: Geospatial Analysis of Underserved Populations in New York State.

Authors:  Kayley Abell-Hart; Sina Rashidian; Dejun Teng; Richard N Rosenthal; Fusheng Wang
Journal:  JMIR Public Health Surveill       Date:  2022-04-12

4.  Opioid Use Disorder Education for Students and the Future of Opioid Overdose Treatment.

Authors:  Neha Balapal; Amala Ankem; Saishravan Shyamsundar; Shuhan He
Journal:  JMIR Med Educ       Date:  2022-07-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.